ATE535520T1 - Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung - Google Patents
Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellungInfo
- Publication number
- ATE535520T1 ATE535520T1 AT07805959T AT07805959T ATE535520T1 AT E535520 T1 ATE535520 T1 AT E535520T1 AT 07805959 T AT07805959 T AT 07805959T AT 07805959 T AT07805959 T AT 07805959T AT E535520 T1 ATE535520 T1 AT E535520T1
- Authority
- AT
- Austria
- Prior art keywords
- salt
- crystal
- production
- crystals
- phenoxypyridine derivative
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- MEAAWTRWNWSLPF-UHFFFAOYSA-N 2-phenoxypyridine Chemical class C=1C=CC=NC=1OC1=CC=CC=C1 MEAAWTRWNWSLPF-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 abstract 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000000704 physical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/508,322 US7855290B2 (en) | 2005-08-24 | 2006-08-23 | Pyridine derivatives and pyrimidine derivatives (3) |
| JP2007036690 | 2007-02-16 | ||
| US89076907P | 2007-02-20 | 2007-02-20 | |
| PCT/JP2007/066185 WO2008023698A1 (en) | 2006-08-23 | 2007-08-21 | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535520T1 true ATE535520T1 (de) | 2011-12-15 |
Family
ID=56291007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07805959T ATE535520T1 (de) | 2006-08-23 | 2007-08-21 | Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8377938B2 (de) |
| EP (1) | EP2062886B1 (de) |
| JP (1) | JP5190365B2 (de) |
| KR (1) | KR101380444B1 (de) |
| CN (1) | CN101454311B (de) |
| AT (1) | ATE535520T1 (de) |
| AU (1) | AU2007288793B2 (de) |
| CA (1) | CA2661333C (de) |
| ES (1) | ES2375284T3 (de) |
| IL (1) | IL197141A (de) |
| WO (1) | WO2008023698A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| CN101198590B (zh) * | 2005-08-24 | 2012-05-09 | 卫材R&D管理有限公司 | 吡啶衍生物及嘧啶衍生物（3） |
| CA2620594C (en) * | 2005-09-01 | 2012-08-21 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition having improved disintegratability |
| AU2006309551B2 (en) | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| CA2661333C (en) | 2006-08-23 | 2014-08-05 | Eisai R&D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
| WO2008026748A1 (en) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| US7790885B2 (en) * | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| JP2009132660A (ja) * | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| JP2009203226A (ja) * | 2008-01-31 | 2009-09-10 | Eisai R & D Management Co Ltd | ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤 |
| EP2248810A4 (de) * | 2008-02-18 | 2011-05-25 | Eisai R&D Man Co Ltd | Verfahren zur herstellung eines phenoxypyridin-derivats |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| US8247000B2 (en) * | 2009-04-10 | 2012-08-21 | Cypress Pharmaceutical, Inc. | Phosphate-binding magnesium salts and uses thereof |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| SG185073A1 (en) | 2010-04-29 | 2012-12-28 | Deciphera Pharmaceuticals Llc | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| CN103003253A (zh) * | 2010-08-05 | 2013-03-27 | 贝林格尔.英格海姆国际有限公司 | 2-{2-[[(4-甲氧基-2,6-二甲基苯基)磺酰基]-(甲基)氨基]乙氧基}-n-甲基-n-[3-(4-甲基哌嗪-1-基)环己基]乙酰胺的酸加成盐及其作为缓激肽b1受体拮抗剂的用途 |
| JPWO2012133416A1 (ja) | 2011-03-29 | 2014-07-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェノキシピリジン誘導体の製造方法（３） |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| US9394318B2 (en) | 2012-11-30 | 2016-07-19 | Cypress Pharmaceuticals, Inc. | Crystal polymorph of magnesium glycinate dihydrate and process for its preparation |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| CN104557688A (zh) * | 2014-12-25 | 2015-04-29 | 凯莱英医药集团（天津）股份有限公司 | 索拉菲尼中间体的合成方法及用于合成其的化合物a的合成方法 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| ES3001119T3 (es) | 2019-03-28 | 2025-03-04 | Amplia Therapeutics Ltd | Una sal y forma cristalina de un inhibidor de FAK |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR20230092805A (ko) * | 2021-12-17 | 2023-06-26 | 주식회사 대웅제약 | (2R, 3S)-2-(3-(4,5-디클로로-1H-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352991B1 (en) | 1997-01-08 | 2002-03-05 | Wayne State University | 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| US6599902B2 (en) | 2001-05-30 | 2003-07-29 | Sugen, Inc. | 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| AU2002313249B2 (en) * | 2001-06-22 | 2008-08-21 | Kirin Pharma Kabushiki Kaisha | Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
| JP3923898B2 (ja) | 2002-01-18 | 2007-06-06 | 株式会社東芝 | 画像符号化方法及び装置 |
| US6790852B2 (en) | 2002-04-18 | 2004-09-14 | Hoffmann-La Roche Inc. | 2-(2,6-dichlorophenyl)-diarylimidazoles |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| ES2353690T3 (es) | 2002-10-03 | 2011-03-04 | Neuropharmacology Services, Llc | Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger. |
| DK1603570T5 (da) | 2003-02-26 | 2013-12-09 | Sugen Inc | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| EP1473043A1 (de) | 2003-04-29 | 2004-11-03 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmazeutische Kombination zur Behandlung von Krankheiten die mit Zellproliferation, Migration oder Apoptose der Myeloma Zellen oder Angiogenese verbunden sind |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| MXPA06000276A (es) | 2003-07-02 | 2006-04-07 | Sugen Inc | Indolinona hidrazidas como inhibidores de c-met. |
| JP2007516180A (ja) | 2003-07-02 | 2007-06-21 | スゲン，インコーポレイティド | ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類 |
| US7037909B2 (en) | 2003-07-02 | 2006-05-02 | Sugen, Inc. | Tetracyclic compounds as c-Met inhibitors |
| EP1641759B1 (de) | 2003-07-07 | 2014-03-12 | Merck Patent GmbH | Malonamidderivate |
| CA2536470A1 (en) | 2003-08-15 | 2005-02-24 | Vertex Pharmaceuticals Incorporated | Pyrrole compositions useful as inhibitors of c-met |
| EP2210607B1 (de) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| US7531532B2 (en) | 2004-02-27 | 2009-05-12 | Eisai R&D Management Co., Ltd. | Pyridine derivative and pyrimidine derivative |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| WO2005115478A2 (en) | 2004-05-11 | 2005-12-08 | The Regents Of The University Of California | Methods and compositions for autism spectrum disorders |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7977345B2 (en) * | 2004-07-02 | 2011-07-12 | Exelixis, Inc. | c-MET modulators and method of use |
| DE102004045193B3 (de) | 2004-09-17 | 2005-11-17 | Siemens Ag | Push-To-Talk-Over-Cellular (PoC) Verfahren |
| JP2008521900A (ja) * | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| JP2007042751A (ja) | 2005-08-01 | 2007-02-15 | Hitachi Cable Ltd | 半導体発光素子 |
| CN101198590B (zh) | 2005-08-24 | 2012-05-09 | 卫材R&D管理有限公司 | 吡啶衍生物及嘧啶衍生物（3） |
| PL1959955T3 (pl) | 2005-12-05 | 2011-04-29 | Pfizer Prod Inc | Sposób traktowania nieprawidłowego wzrostu komórek |
| CA2661333C (en) | 2006-08-23 | 2014-08-05 | Eisai R&D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
| US7790885B2 (en) * | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| AU2008217931A1 (en) | 2007-02-23 | 2008-08-28 | Eisai R & D Management Co., Ltd. | Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of HGFR gene |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| JP2009203226A (ja) | 2008-01-31 | 2009-09-10 | Eisai R & D Management Co Ltd | ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤 |
| EP2248810A4 (de) | 2008-02-18 | 2011-05-25 | Eisai R&D Man Co Ltd | Verfahren zur herstellung eines phenoxypyridin-derivats |
-
2007
- 2007-08-21 CA CA2661333A patent/CA2661333C/en not_active Expired - Fee Related
- 2007-08-21 CN CN200780019200XA patent/CN101454311B/zh not_active Expired - Fee Related
- 2007-08-21 AU AU2007288793A patent/AU2007288793B2/en not_active Ceased
- 2007-08-21 WO PCT/JP2007/066185 patent/WO2008023698A1/ja not_active Ceased
- 2007-08-21 AT AT07805959T patent/ATE535520T1/de active
- 2007-08-21 EP EP07805959A patent/EP2062886B1/de active Active
- 2007-08-21 KR KR1020087027527A patent/KR101380444B1/ko not_active Expired - Fee Related
- 2007-08-21 ES ES07805959T patent/ES2375284T3/es active Active
- 2007-08-21 JP JP2008530917A patent/JP5190365B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-14 US US12/031,568 patent/US8377938B2/en not_active Expired - Fee Related
-
2009
- 2009-02-19 IL IL197141A patent/IL197141A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2008023698A1 (ja) | 2010-01-14 |
| IL197141A (en) | 2014-01-30 |
| CA2661333C (en) | 2014-08-05 |
| EP2062886A1 (de) | 2009-05-27 |
| AU2007288793B2 (en) | 2012-04-19 |
| KR101380444B1 (ko) | 2014-04-01 |
| IL197141A0 (en) | 2009-11-18 |
| KR20090054946A (ko) | 2009-06-01 |
| JP5190365B2 (ja) | 2013-04-24 |
| EP2062886B1 (de) | 2011-11-30 |
| US20080318924A1 (en) | 2008-12-25 |
| AU2007288793A1 (en) | 2008-02-28 |
| ES2375284T3 (es) | 2012-02-28 |
| CN101454311B (zh) | 2013-03-27 |
| CN101454311A (zh) | 2009-06-10 |
| WO2008023698A1 (en) | 2008-02-28 |
| CA2661333A1 (en) | 2008-02-28 |
| US8377938B2 (en) | 2013-02-19 |
| EP2062886A4 (de) | 2010-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE535520T1 (de) | Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung | |
| WO2008071918A8 (en) | Pyrido-pyrazine derivatives useful as herbicidal compounds | |
| WO2008093024A3 (fr) | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2-carboxamides, leur préparation et leur application en therapeutique | |
| PH12014501719B1 (en) | Pyridone derivatives | |
| GEP20105074B (en) | Pyrimidinyl aryl urea derivatives being fgf inhibitors | |
| ME00590A (en) | N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | |
| WO2008058096A3 (en) | Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands | |
| MY157073A (en) | Conversion method | |
| CY1111528T1 (el) | 1-αζα-δικυκλο [3.3.1] εννεανια | |
| TN2014000058A1 (en) | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes | |
| HK1199025A1 (en) | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors | |
| PL1960379T3 (pl) | Pochodne N-(1-alkilo-2-fenyloetylo)-karboksamidu i ich zastosowanie jako fungicydów | |
| MX2009013869A (es) | Proceso para hacer 2-amino-tiazolonas sustituidas. | |
| EP2602254A4 (de) | Heterocyclische verbindung | |
| TNSN07395A1 (en) | Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives | |
| DE502007003531D1 (de) | Verfahren zum herstellen von alkylaniliden aus halogenbenzolderivaten | |
| ATE532516T1 (de) | Verfahren zur synthese von glyt-1-hemmern | |
| TW200744996A (en) | Improved process for the production of nitroisourea derivative | |
| IL186832A0 (en) | Process for the preparation of a carboxamide derivatives | |
| WO2008101975A3 (en) | New n-(3-phenylpropyl)benzamide derivatives | |
| WO2008063548A3 (en) | 5, 6, or 7-substituted-s- (hetero)arylisoquinolinamine derivatives as antitumor agents | |
| ATE386735T1 (de) | Substituierte benzoylureidopyridyl-piperidin- und pyrrolidin-carbons urederivate, verfahren zu deren herstellung und deren v erwendung | |
| ATE444964T1 (de) | 5-pyridinyl-1-azabicycloä3.2.1üoctan-derivate, herstellungsverfahren und deren verwendung für therapeutika | |
| WO2008003744A3 (en) | N-methyl benzamide derivatives useful as fungicides | |
| ATE492556T1 (de) | Verfahren zur glycosidierung von colchicin und thiocolchicin |